Head-To-Head Contrast: Becton, Dickinson and Company (NYSE:BDX) and United American Healthcare (OTCMKTS:UAHC)

United American Healthcare (OTCMKTS:UAHC) and Becton, Dickinson and Company (NYSE:BDX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for United American Healthcare and Becton, Dickinson and Company, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United American Healthcare	0	0	0	0	N/A
Becton, Dickinson and Company	0	1	7	0	2.88

Becton, Dickinson and Company has a consensus price target of $279.50, indicating a potential upside of 18.27%. Given Becton, Dickinson and Company’s higher possible upside, analysts plainly believe Becton, Dickinson and Company is more favorable than United American Healthcare.

Insider and Institutional Ownership

87.0% of Becton, Dickinson and Company shares are held by institutional investors. 14.3% of United American Healthcare shares are held by insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares United American Healthcare and Becton, Dickinson and Company’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United American Healthcare	N/A	N/A	N/A	N/A	N/A
Becton, Dickinson and Company	$19.83 billion	3.44	$1.48 billion	$4.54	52.06

Becton, Dickinson and Company has higher revenue and earnings than United American Healthcare.

Risk & Volatility

United American Healthcare has a beta of -1.41, suggesting that its stock price is 241% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

Profitability

This table compares United American Healthcare and Becton, Dickinson and Company’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
United American Healthcare	N/A	N/A	N/A
Becton, Dickinson and Company	7.13%	14.49%	6.92%

Summary

Becton, Dickinson and Company beats United American Healthcare on 8 of the 9 factors compared between the two stocks.

About United American Healthcare

United American Healthcare Corporation, through its subsidiaries, provides contract manufacturing services to the medical device industry. It also focuses on the production of natural rubber. The company was incorporated in 1983 and is based in Chicago, Illinois.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.